scholarly journals Discontinuing Long-Term GH Replacement Therapy—A Randomized, Placebo-Controlled Crossover Trial in Adult GH Deficiency

2012 ◽  
Vol 97 (9) ◽  
pp. 3185-3195 ◽  
Author(s):  
Helena Filipsson Nyström ◽  
Edna J. L. Barbosa ◽  
Anna G. Nilsson ◽  
Lise-Lott Norrman ◽  
Oskar Ragnarsson ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Crossover Trial ◽  
Gh Deficiency ◽  
Gh Replacement ◽  
Adult Gh Deficiency

scholarly journals Successful pregnancy and delivery in a patient with adult GH deficiency: role of GH replacement therapy

2011 ◽  
Vol 58 (1) ◽  
pp. 65-68 ◽  
Author(s):  
Satoko Sakai ◽  
Takanobu Wakasugi ◽  
Kunimasa Yagi ◽  
Akitsu Ohnishi ◽  
Naoko Ito ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Gh Deficiency ◽  
Successful Pregnancy ◽  
Gh Replacement ◽  
Adult Gh Deficiency ◽  
Pregnancy And Delivery

Long-term effects of GH replacement therapy on thyroid function in children with GH deficiency

2019 ◽  
Author(s):  
Ida D'Acunzo ◽  
Federica Anselmi ◽  
Valeria Gaeta ◽  
Flavia Barbieri ◽  
Gian Paolo Ciccarelli ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Thyroid Function ◽  
Gh Deficiency ◽  
Long Term Effects ◽  
Gh Replacement

The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: Results of the German KIMS database

2011 ◽  
Vol 21 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Christin Spielhagen ◽  
Christian Schwahn ◽  
Kristin Möller ◽  
Nele Friedrich ◽  
Thomas Kohlmann ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Replacement Therapy ◽  
Gh Deficiency ◽  
Gh Replacement

scholarly journals A Case With Adult GH Deficiency Complicated With Osteogenesis Imperfecta: Effect of GH Replacement on Bone Mineral Density

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A564-A564
Author(s):  
Tomomi Taguchi ◽  
Takuya Toki ◽  
Akinori Hayashi ◽  
Koji Takano
Keyword(s):  
Bone Mineral Density ◽  
Osteogenesis Imperfecta ◽  
Replacement Therapy ◽  
Bone Mineral ◽  
Gh Deficiency ◽  
Stimulation Test ◽  
Z Score ◽  
Mineral Density ◽  
Gh Replacement ◽  
Adult Gh Deficiency

Abstract Background: Osteogenesis imperfecta (OI) is an inherited connective tissue disorder with many phenotypic presentations. Bisphosphonates are the mainstay of pharmacologic fracture prevention therapy, although they aren’t officially approved for the treatment of OI. Clinical Case: The patient was born by breech delivery. After he had multiple fractures at the age of two years, he was diagnosed with osteogenesis imperfecta (OI) type I by genetic analysis (c.1299 + 1G> A mutation in the COL1A1 gene). On the growth curve, his height fell below -2SD at the age of six years. When he was 12 years old, he visited another hospital because of short stature (Hight 119 cm: -2.7SD). Pituitary MRI revealed pituitary stalk disruption and pituitary atrophy. Endocrinological examinations (ITT, TRH, LHRH, arginine stimulation tests) showed severe GH deficiency. Growth hormone replacement therapy was started. At the age of 16 years, he was diagnosed to have central hypothyroidism and central diabetes insipidus, and levothyroxine and DDAVP were started. His bone mineral density of the lumbar spine was 0.546 g/cm2, and alendronate was started. At the age of 17, central hypogonadism was diagnosed by LHRH stimulation test, and HCG injections were initiated. His bone mineral density continued to increase by GH replacement, HCG injections and bisphosphonate and reached 0.820 g/cm2 (Z-score: -0.27) by the age of 18 years. GH replacement was discontinued (final height 180 cm). At that age, his bone mineral density declined to 0.717 g/cm2 at the age of 25 years, although he stayed on an alendronate and HCG injections. At that time, total testosterone 890 ng/dL (142<n<923 ng/dL) was within normal range, but IGF-1 level was below the lower limit (44 ng/mL; -4.6SD, 225<n<337 ng/mL). He was referred to our hospital for transition to adult endocrine care. Endocrinologic evaluation revealed low serum cortisol level in the early morning (2.26 µg/dL, 7.07<n<19.6 μg/dL). GH-releasing peptide-2 stimulation test revealed severe GH deficiency (peak GH 0.18 ng/mL, n> 15 ng/mL (1)) and replacements with GH and hydrocortisone were initiated. After the GH replacement, the bone mineral density started to increase to 0.954 g/cm2 (Z-score: -0.5). Conclusion: So far as we know, this is the first case report of OI with panhypopituitarism treated with GH and bisphosphonate. This case suggests that bisphosphonate alone is not sufficient to maintain bone mineral density complicated with both OI and severe GHD. GH replacement therapy was inevitable to increase bone mineral density in this patient. Reference: (1) Kazuo Chihara et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol.2007;157;19-27.

scholarly journals Effect of long-term GH replacement therapy on cardiovascular outcomes in isolated GH deficiency compared with multiple pituitary hormone deficiencies: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults

2014 ◽  
Vol 171 (2) ◽  
pp. 151-160 ◽  
Author(s):  
Christa C van Bunderen ◽  
Carline J van den Dries ◽  
Martijn W Heymans ◽  
Anton A M Franken ◽  
Hans P F Koppeschaar ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Replacement Therapy ◽  
Clinical Presentation ◽  
Gh Deficiency ◽  
National Registry ◽  
Pituitary Hormone ◽  
Gh Treatment ◽  
Gh Replacement

ObjectiveIsolated GH deficiency (IGHD) could provide a model to investigate the influence of GH deficiency per se and the effect of GH replacement therapy without the influence from other pituitary hormone deficiencies or their treatment. The aim of this study is to address the questions about differences between IGHD and multiple pituitary hormone deficiencies (MPHDs) in clinical presentation and in responsiveness to GH treatment.DesignA nationwide surveillance study was carried out to describe the difference in the clinical presentation and responsiveness to GH treatment of patients with IGHD and MPHDs.MethodsThe Dutch National Registry of GH Treatment in Adults was founded in 1998 to gain more insight into long-term efficacy and safety of GH therapy. Out of 2891 enrolled patients, 266 patients with IGHD at the start of GH treatment were identified and compared with 310 patients with MPHDs. Cardiovascular indices will be investigated at baseline and during long-term follow-up, including body composition, lipid profile, glucose metabolism, blood pressure, and morbidity.ResultsPatients with IGHD and MPHDs were demonstrated to be different entities at clinical presentation. Metabolically, patients with MPHDs had a larger waist circumference, lower HDL cholesterol level, and higher triglyceride level. The effect of GH treatment was comparable between patient groups. GH seems to protect against rising lipid levels and blood pressure, even after excluding patients using corresponding concomitant medication. The risk for cardiovascular disease or diabetes mellitus during follow-up was not different between patients with IGHD and MPHDs.ConclusionsPatients with IGHD had a less impaired metabolic profile than patients with MPHDs at baseline. Influence of other pituitary hormone replacement therapies on the effect of GH treatment is not demonstrated.

Sign in / Sign up

Export Citation Format

Share Document